- Home
- NMI vs ALXO Comparison
NMI vs ALXO Comparison
Compare NMI & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMI
- ALXO
- Stock Information
- Founded
- NMI 1988
- ALXO 2015
- Country
- NMI United States
- ALXO United States
- Employees
- NMI N/A
- ALXO N/A
- Industry
- NMI Trusts Except Educational Religious and Charitable
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- NMI Finance
- ALXO Health Care
- Exchange
- NMI Nasdaq
- ALXO Nasdaq
- Market Cap
- NMI 101.7M
- ALXO 102.3M
- IPO Year
- NMI N/A
- ALXO 2020
- Fundamental
- Price
- NMI $10.01
- ALXO $1.73
- Analyst Decision
- NMI
- ALXO Strong Buy
- Analyst Count
- NMI 0
- ALXO 6
- Target Price
- NMI N/A
- ALXO $3.30
- AVG Volume (30 Days)
- NMI 28.4K
- ALXO 532.0K
- Earning Date
- NMI 01-01-0001
- ALXO 11-10-2025
- Dividend Yield
- NMI 4.10%
- ALXO N/A
- EPS Growth
- NMI N/A
- ALXO N/A
- EPS
- NMI N/A
- ALXO N/A
- Revenue
- NMI N/A
- ALXO N/A
- Revenue This Year
- NMI N/A
- ALXO N/A
- Revenue Next Year
- NMI N/A
- ALXO N/A
- P/E Ratio
- NMI N/A
- ALXO N/A
- Revenue Growth
- NMI N/A
- ALXO N/A
- 52 Week Low
- NMI $8.30
- ALXO $0.40
- 52 Week High
- NMI $10.05
- ALXO $2.27
- Technical
- Relative Strength Index (RSI)
- NMI 59.61
- ALXO 54.31
- Support Level
- NMI $10.00
- ALXO $1.56
- Resistance Level
- NMI $10.11
- ALXO $1.78
- Average True Range (ATR)
- NMI 0.06
- ALXO 0.18
- MACD
- NMI -0.01
- ALXO -0.04
- Stochastic Oscillator
- NMI 18.21
- ALXO 34.37
About NMI Nuveen Municipal Income Fund Inc.
Nuveen Municipal Income Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.